TRML
Tourmaline Bio, Inc. (TRML) Business Model Analysis (2026)
Overall Score
Revenue Model
The company appears to have a very low-revenue or pre-revenue profile, with revenue per share at 0 and price-to-sales at 0, making the top-line model hard to assess from current metrics.
No material month-over-month change is evident in the fresh data.
Profitability
TTM margins are all reported at 0, while return on assets (-17.1%), return on equity (-17.1%), and return on invested capital (-20.1%) remain deeply negative, indicating an unprofitable business model.
No material month-over-month change is evident in the fresh data.
Balance Sheet Strength
Liquidity is very strong, with a current ratio of 24.7x and cash ratio of 3.1x, suggesting ample near-term coverage.
Leverage is minimal, with debt-to-equity at 0.0006 and debt-to-assets at 0.0005, though solvency ratio is negative in the reported data.
No material month-over-month change is evident in the fresh data.
Cash Flow Quality
Operating cash flow and free cash flow are both negative, with free cash flow yield at -3.4% and operating cash flow ratio at -4.15x, indicating weak cash generation.
Income quality is relatively high at 0.91, but it does not offset the negative cash flow profile.
No material month-over-month change is evident in the fresh data.
Capital Efficiency
Returns on capital remain negative, with ROIC at -20.1% and ROCE at -20.1%, showing poor capital efficiency.
Asset turnover is 0 and operating margins are 0, reinforcing that the business is not yet converting capital into operating output.
No material month-over-month change is evident in the fresh data.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Tourmaline Bio, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

